Rapport Therapeutics to Attend Major Investor Conferences
BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon.
Details of Upcoming Conferences
The company will engage in a fireside chat at the Jefferies Global Healthcare Conference, scheduled for June 4th at 10:30 a.m. Eastern Time. This event, held in New York City, will provide an excellent platform for Rapport Therapeutics to present its innovative strategies and insights to potential investors.
Goldman Sachs Annual Global Healthcare Conference
Furthermore, the organization is set to participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 10:00 a.m. Eastern Time in Miami. This event is crucial for Rapport Therapeutics as it allows the team to showcase their advancements and connect with other industry leaders.
Accessing the Webcasts
Investors and interested parties are invited to catch the live and archived webcasts from both events via the “Investors” section on Rapport Therapeutics’ official website. It’s a great opportunity for stakeholders to stay informed about the latest developments and strategic directions of the company.
About Rapport Therapeutics
Rapport Therapeutics is not just another clinical-stage biotechnology company; it stands out for its commitment to precision medicine aimed primarily at neurological and psychiatric illnesses. Founded by pioneers in neuroscience, the company leverages groundbreaking discoveries about receptor associated proteins (RAPs) in the brain. These discoveries underpin Rapport’s unique RAP technology platform, facilitating the creation of innovative product candidates that aspire to address common challenges faced in neurology drug development.
Key Product and Pipeline
The heart of Rapport’s precision neuroscience pipeline is their investigational drug, RAP-219. This promising candidate is designed to achieve neuroanatomical specificity, selectively targeting a RAP expressed in distinct brain regions. Currently, the company is focusing on RAP-219 as a potential remedy for refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain.
Moreover, Rapport Therapeutics is pursuing additional preclinical and late-stage discovery programs aimed at addressing prevalent issues such as chronic pain and hearing disorders, underscoring its extensive commitment to innovation.
Contact Information
For further inquiries, you can reach out to:
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
Frequently Asked Questions
What is Rapport Therapeutics known for?
Rapport Therapeutics specializes in developing small molecule precision medicines targeting neurological and psychiatric disorders.
What upcoming conferences will Rapport Therapeutics attend?
They will participate in the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference.
How can investors access the webcasts of the conferences?
Investors can find live and archived webcasts in the “Investors” section of Rapport Therapeutics’ official website.
What is RAP-219?
RAP-219 is an investigational drug developed by Rapport Therapeutics aimed at treating conditions like refractory focal epilepsy and bipolar mania.
How does Rapport Therapeutics differentiate itself in the biotechnology field?
The company utilizes its unique RAP technology platform to develop precision medicines that address various limitations in conventional neurology drug discovery.